Trial Profile
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs MRX 34 (Primary) ; Dexamethasone
- Indications Acute myeloid leukaemia; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Colorectal cancer; Liver cancer; Liver metastases; Lung cancer; Lymphoma; Myelodysplastic syndromes; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Mirna Therapeutics
- 02 Apr 2020 Results assessing MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, published in the British Journal of Cancer
- 05 Dec 2016 Results (n=47) published in the Investigational New Drugs.
- 10 Nov 2016 According to Mirna Therapeutics media release, FDA requested a final clinical study report along with risk-benefit summary with sufficient justification for the continued development of MRX34 to remove the clinical hold.